Literature DB >> 2647992

The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.

S G Rains1, G A Wilson, W Richmond, R S Elkeles.   

Abstract

Changes in serum lipoproteins were studied in 14 non-insulin dependent diabetics on long-term metformin therapy, after 6 weeks' placebo, and again 6 weeks after restarting active drug therapy. Withdrawal of metformin resulted in a rise of fasting blood glucose, HbA1, serum total and low density lipoprotein (LDL) cholesterol. Restarting the drug reversed these changes. Multivariate analysis showed that serum total and LDL cholesterol varied with treatment but not with glycaemic control. Metformin can lower serum total and LDL cholesterol in non-insulin dependent diabetics and this effect is maintained long term.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647992      PMCID: PMC1292002          DOI: 10.1177/014107688908200213

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  5 in total

1.  Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention.

Authors:  P W Seviour; T K Teal; W Richmond; R S Elkeles
Journal:  Diabet Med       Date:  1988-03       Impact factor: 4.359

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 3.  Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  G Panzram
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

Review 4.  The lipoproteins: predictors, protectors, and pathogens.

Authors:  B Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-22

5.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.

Authors:  G R Warnick; J Benderson; J J Albers
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

  5 in total
  9 in total

1.  Insulin resistance: Is it time for primary prevention?

Authors:  Valentina Mercurio; Guido Carlomagno; Valeria Fazio; Serafino Fazio
Journal:  World J Cardiol       Date:  2012-01-26

Review 2.  Treatment of diabetes: the effect on serum lipids and lipoproteins.

Authors:  P K Merrin; R S Elkeles
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

Review 3.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 4.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 5.  Management of dyslipidemia in people with type 2 diabetes mellitus.

Authors:  Fredrick L Dunn
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

Review 6.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

Authors:  C J Dunn; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 7.  Metabolic syndrome in the elderly.

Authors:  Matthew Bechtold; John Palmer; Joshua Valtos; Catherine Iasiello; James Sowers
Journal:  Curr Diab Rep       Date:  2006-02       Impact factor: 4.810

8.  Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.

Authors:  L S Hermann; J E Karlsson; A Sjöstrand
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Cellular and Molecular Mechanisms of Metformin Action.

Authors:  Traci E LaMoia; Gerald I Shulman
Journal:  Endocr Rev       Date:  2021-01-28       Impact factor: 19.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.